IRAK1: Oncotarget in MDS and AML

Oncotarget. 2014 Apr 15;5(7):1699-700. doi: 10.18632/oncotarget.1880.

Publication types

  • Editorial

MeSH terms

  • Aniline Compounds / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Transformed
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Humans
  • Interleukin-1 Receptor-Associated Kinases / antagonists & inhibitors*
  • Interleukin-1 Receptor-Associated Kinases / metabolism*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Molecular Targeted Therapy
  • Myelodysplastic Syndromes / drug therapy*
  • Protein Kinase Inhibitors / pharmacology*
  • Signal Transduction
  • Sulfonamides / pharmacology

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Sulfonamides
  • IRAK1 protein, human
  • Interleukin-1 Receptor-Associated Kinases
  • navitoclax